The United States-based drugmaker Pfizer that claimed 90 percent efficiency for its COVID-19 vaccine, has launched a pilot project in the USA. Pfizer seeks to address and face the distribution challenges that require ultra-cold storage for the vaccine.
“We are hopeful that results from this vaccine delivery pilot will serve as the model for the other US states and international governments, as they prepare to implement effective COVID-19 vaccine programs,” Pfizer said in a statement on Monday.
The US-based pharma company Pfizer has launched a vaccine against COVID-19. The vaccine named BNT162b2 has shown good results in the first interim efficacy analysis conducted on November 8, 2020, by an external independent Data Monitoring Committee (DMC) from the Phase 3 clinical study. The main challenge in its distribution is that it must be stored at -70 degrees Celsius (minus 94°F), significantly below the standard for vaccines of 2-8 degrees Celsius (36-46°F).
The drugmaker has picked up 4 states of the USA that includes Rhode Island, Texas, New Mexico, and Tennessee for the program. The distribution challenges will help the company to deal with the different challenges of the diversity of populations, immunization infrastructure, and the need to reach individuals in varied urban and rural settings.
The company said that it will have enough safety data from the ongoing large scale trials of the final stage. So the company can apply for emergency use authorization (EUA) for the vaccine.